Feng Zhang spinout brings in $215M for gene editing

Nearly six years after launching from the lab of gene-editing pioneer Feng Zhang, Arbor Biotechnologies is charging ahead with a massive Series B round: $215 million co-led by Temasek, Ally Bridge Group and TCG Crossover.